Evidence map›Paper›PMID 35906549›Full record

ArticleBMC cancer2022

A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.

Yun Guan, Mingyuan Pan, Jun Yang, Qiuxia Lu, Liangfu Han, Ying Liu, Jing Li, Huaguang Zhu, Xiu Gong, Guanghai Mei and 6 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04547621 (The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04547621 phase1 / phase2unknown statusnot on this map

The Combination of Hypofractionated Stereotactic Radiotherapy and Chemoradiotherapy Using Intensity-Modulated Radiotherapy for Newly Diagnosed Glioblastoma Multiforme: A Prospective, Single-Center, Single-Arm Phase II Clinical Trial

TypeinterventionalSponsorHuashan HospitalRan2020 to 2024Enrolled50ConditionsGlioma, MalignantArmsRadiation, Temozolomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Yun Guan *CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Mingyuan Pan *CyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Jun YangCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Qiuxia LuFoshan Chancheng Hospital, Foshan, China.
Liangfu HanFoshan Chancheng Hospital, Foshan, China.
Ying LiuDepartment of Pathology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jing LiCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Huaguang ZhuCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Xiu GongCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Guanghai MeiCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Xiaoxia LiuCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Li PanCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Jiazhong DaiCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Yang WangCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China.
Enmin WangCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China. wangem@fudan.edu.cn.
Xin WangCyberKnife Center, Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, 12 Wulumuqi Road (M), Shanghai, 200040, China. wangxinck@fudan.edu.cn.
Fudan University · CNFoshan Hospital of TCM · CNHuashan Hospital · CNShanghai Center for Brain Science and Brain-Inspired Technology · CNShanghai Clinical Research Center · CNShanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe most frequently diagnosed primary brain tumor is glioblastoma (GBM). Nearly all patients experience tumor recurrence and up to 90% of which is local recurrence. Thus, increasing the therapeutic ratio of radiotherapy using hypofractionated stereotactic radiotherapy (HSRT) can reduce treatment time and may increase tumor control and improve survival. To evaluate the efficacy and toxicity of the combination of HSRT and intensity-modulated radiotherapy (IMRT) with temozolomide after surgery in GBM patients and provide evidence for further randomized controlled trials. METHODS/

designHSCK-010 is an open-label, single-arm phase II trial (NCT04547621) which includes newly diagnosed GBM patients who underwent gross total resection. Patients will receive the combination of 30 Gy/5fx HSRT, and 20 Gy/10fx IMRT adjuvant therapy with concurrent temozolomide and adjuvant chemotherapy. The primary endpoint is overall survival (OS). Secondary outcomes include progression-free survival (PFS) rate, objective-response rate (ORR), quality of life (Qol) before and after the treatment, cognitive function before and after the treatment, and rate of treatment-related adverse events (AE). The combination of HSRT and IMRT with temozolomide can benefit the patients after surgery with good survival, acceptable toxicity, and reduced treatment time.

trial registrationNCT04547621 . Registered on 14 September 2020.

Indexed as

Brain NeoplasmsGlioblastomaRadiotherapy, Intensity-ModulatedAntineoplastic Agents, AlkylatingChemoradiotherapyClinical Trials, Phase II as TopicHumansQuality of LifeTemozolomideAntineoplastic Agents, AlkylatingTemozolomideAdjuvant chemoradiotherapyHypofractionated stereotactic radiotherapyNewly diagnosed glioblastoma

Identifiers

PMID35906549
PMCPMC9335974
OpenAlexW4288535457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.